Figure 2.

Serial changes in the proportion of patients with metabolic syndrome components associated with withdrawal and reinstitution of thyroid hormone in patients with differentiated thyroid cancer who received radioactive iodine ablation following total thyroidectomy (n = 48). Proportion of patients with (a) waste circumference (WC) ≥ 90 cm among males and ≥ 80 cm among females; (b) blood pressure (BP) ≥ 130/85 mmHg; (c) fasting plasma glucose (FPG) ≥ 100 mg/dl; (d) triglyceride (TG) ≥ 150 mg/dl; (e) high-density lipoprotein-cholesterol (HDL-C) levels < 40 mg/dl among males and < 50 mg/dl among females; and (f) metabolic syndrome defined according to the National Cholesterol Education Program Adult Treatment Panel III report.²⁰ Data presented as % patient prevalence. Visit 1, immediately before withdrawal of levothyroxine in preparation for radioactive iodine ablation; Visit 2, at 4 weeks following levothyroxine withdrawal (on day of radiotherapy); and Visit 3, at 4 weeks following reinstitution of levothyroxine. *P < 0.05 versus Visit 1; ^#P < 0.05 versus Visit 2 (χ²-test).